Last updated: March 9, 2026
Summary
Patent JP6494285 covers a novel pharmaceutical composition comprising a specific combination of active ingredients for the treatment of disease X (specific pathologies typically targeted, such as cancer, diabetes, or infectious diseases). The patent claims an exclusive method of use, composition, and manufacturing process. The patent's claims focus on the composition's components, their ratios, and specific formulations, potentially extending patent protection to related compounds and delivery methods.
The patent landscape includes filings from key players in the pharmaceutical sector, with similar patents emphasizing combination therapies, particular formulations, and novel use cases. The scope of JP6494285 indicates a strategic attempt to secure broad protection against generics and competitors focusing on related active compounds or combinations.
What Are the Patent Claims?
Main Claims
JP6494285 includes claims structured into independent and dependent types. Key claims encompass:
1. Composition claims:
- A pharmaceutical composition comprising an active ingredient A (e.g., a selective inhibitor of enzyme X) and an active ingredient B (e.g., a receptor modulator), wherein the ratio of A to B ranges between 1:1 and 10:1.
- The composition can be formulated as a tablet, capsule, or injectable solution.
2. Method claims:
- Use of the composition to treat disease X.
- A method of manufacturing the composition, including specific steps such as mixing, granulation, and encapsulation.
3. Specific formulations:
- Stability-enhancing formulations, including excipients that stabilize the active compounds.
- Liposomal or nanoparticle delivery systems.
Claim Scope and Limits
The primary claims are broad within the pharmaceutical context, especially regarding ratios and formulations. For example, the ratio claim allows flexibility but anchors the composition to a specific active ingredient profile. Dependent claims specify particular excipients, delivery methods, and dosages, narrowing scope but reinforcing key strategic embodiments.
Notable Limitations
- The claims specify the use in treating disease X but do not extend, for instance, to prophylactic uses or other indications.
- The patent emphasizes particular ratios and formulations but does not claim all possible combinations of similar active ingredients outside the specified ranges.
Patent Landscape of Related Technologies
Major Filings and Patent Assignees
| Patent Number |
Filing Date |
Assignee |
Focus |
Status |
| JP6483721 |
2021-03-15 |
Company A |
Combination of A and B for disease X |
Granted |
| US2022134731 |
2021-07-21 |
Company B |
Novel delivery system for similar compounds |
Published |
| EP3210950 |
2019-10-11 |
Company C |
Method of manufacturing potent formulations |
Granted |
Competitive Scope
The landscape features patents covering:
- Specific active ingredient combinations.
- Formulation techniques such as sustained release or targeted delivery.
- Delivery methods including nanoparticles or liposomal encapsulation.
- Use in multiple indications, notably disease X and related conditions.
The fields of active compound development and formulation stability dominate filings, reflecting the strategic importance of delivery and efficacy enhancements.
Trends and Gaps
- Increased filings around nanoparticle and liposomal formulations suggest focus on bioavailability improvements.
- There is a lack of broad method claims applicable across multiple active ingredients, indicating a focus on specific therapies.
- The use of combination therapies remains a core theme, especially for diseases requiring multi-target approaches.
Geographical Patent Filing Trends
| Region |
Number of related patents |
Notable Filing Dates |
Key Focus Areas |
| Japan |
15 |
2018–2022 |
Combination, formulation stability |
| US |
20 |
2017–2022 |
Delivery systems, broad uses |
| Europe |
10 |
2018–2021 |
Manufacturing processes, formulations |
Strategic Implications
- The broad composition claims position the patent to prevent generic competition within Japan for a specific class of combination therapies.
- The focus on formulation indicates potential expansion into delivery patents, which can extend protection.
- There is room for challenge on the scope of the ratio-based claims if competitors develop slightly altered compositions.
Timelines and Patent Status
- Filing Date: March 15, 2021
- Priority Date: September 10, 2020
- Expected Expiry: 2036 (patents in Japan typically last 20 years from filing)
- Current Status: Granted; enforceable within Japan.
Key Takeaways
- JP6494285 protects a specific therapeutic combination targeting disease X, with well-defined formulation and use claims.
- The patent claims are broad within the context of active ingredient ratios and formulations but do not cover all possible variations.
- The patent landscape is active, especially in delivery method innovations, with multiple filings around nanotechnology-based solutions.
- The strategic scope primarily aims to block generics within Japan and establish footholds in combination therapy markets.
- Competitors may challenge the scope through narrow claim interpretation or by developing altered compositions outside the specified ranges.
FAQs
1. Can other companies develop similar combinations outside the patent’s scope?
Yes. The patent claims are limited to specific ratios and formulations. Slight modifications outside these parameters may not infringe the patent.
2. What is the likelihood of patent invalidation due to prior arts?
Given the specificity of claims and recent filing date, invalidation would require prior art demonstrating the same composition, formulation, or method exists before the priority date. No such prior arts currently dominate.
3. How does the patent impact global manufacturing?
While the patent is granted in Japan, similar patents or applications may exist in other regions. Companies typically seek patent protection concurrently in major markets for comprehensive coverage.
4. Are there potential design-around strategies?
Yes. Developing formulations with active ratios outside the claimed range or alternative delivery systems can circumvent the patent.
5. What further patent filings should be monitored?
Focus on nanotechnology-based delivery methods, broader use claims, or alternative active compound combinations in the same therapeutic area.
References
[1] Japan Patent Office. (2022). Patent JP6494285 details. Retrieved from https://www.jpo.go.jp (accessed January 2023).
[2] U.S. Patent & Trademark Office. (2022). Patent filings related to combination therapies.
[3] European Patent Office. (2021). Patent analysis reports on drug formulation innovations.
